Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Zanubrutinib with R-CHOP for the Treatment of Patients with Diffuse Large B-Cell Lymphoma

Trial Status: active

This phase II trial tests how well adding zanubrutinib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) works in treating patients with diffuse large B-cell lymphoma. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as those given for R-CHOP, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding zanubrutinib to R-CHOP may kill more cancer cells in patients with diffuse large B-cell lymphoma.